Qynapse (@QYNAPSE) header
Qynapse (@QYNAPSE) profile picture

The future of neuroimaging is here. Qynapse offers groundbreaking peace of mind by providing results you can trust.

FRANCE – USA – CANADA
Joined February 2015
Photo by Qynapse (@QYNAPSE)Photo by Qynapse (@QYNAPSE)Photo by Qynapse (@QYNAPSE)Photo by Qynapse (@QYNAPSE)Photo by Qynapse (@QYNAPSE)Photo by Qynapse (@QYNAPSE)Photo by Qynapse (@QYNAPSE)Photo by Qynapse (@QYNAPSE)Photo by Qynapse (@QYNAPSE)Photo by Qynapse (@QYNAPSE)
Qynapse retweeted
We’re excited to partner with @Qynapse and to add advanced analysis capabilities to our full suite of proven #MedicalImaging services. Read the announcement. https://nitter.cf/t.co/9qLdJnN9wr #clinicaltrials #ChooseCalyx
3
6
Congratulations to @Qynapse for this new publication that brings forward the imaging biomarkers identification for small vessel disease! 👏🙌⬇️ #stroke #MRI #research #cSVD #SHiVA #biomarker
Qynapse is pleased to highlight recently published validation results for QyScore® white matter hyperintensities (WMH) segmentation in NeuroImage: Clinical. Perfect timing for #ACTRIMS next week! 👉 Link to the full article: @ doi.org/10.1016/j.nicl.2022.… #actrimsforum #MS #ai
2
2
We took a leaf from @curtlanglotz's book from 2019 and put together the logos of all exhibitors at @RSNA 2021's AI showcase! Ping us at @CARINGresearch if your logo is missing!
7
14
1
52
#CTAD21 Kick off of the @CTADconference in Boston and livestreamed on the digital platform! ctad-alzheimer.com
4
12
#CTAD21 week starts tomorrow! 😍 Don't miss the chance to hear the latest on therapeutic trials in AD!
5
5
White matter hyperintensities in the splenium (not genu/body) of the corpus callosum predict cognitive decline in memory clinic patients (independently from total WMH) 🧠 ➡️ Poster 57540 #AAIC2021 ➡️ New evidences that WMH in the splenium of the CC need to be further explored !
2
5
16
Qynapse retweeted
The MAGNIMS network is proud to spearhead this landmark transatlantic consensus guidelines - 2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis thelancet.com/journals/laneu…
#Qynapse reaffirmed its commitment to helping advance #MultipleSclerosis (MS) research and overall care, in recognition of #WorldMSDay. Read more here: buff.ly/3icLEfi
2
3
The SHIVA GA concluded. Thank you for your participation and congratulations to all for the progress of the project! 👏 #SHiVA #cSVD @univbordeaux @CHUBordeaux @Inserm @CNRSAquitaine @APHP @InstVisionParis @fealinx_ @Imagine_Eyes @QYNAPSE
New Post: Oral RRMS Therapy Safely Lowers Active Lesions in Phase 2 Trial, Data Show buff.ly/3kkDpN8
3
7
New Post: Sanofi’s BTK Inhibitor Seen to Effectively Reduce Brain Lesions in Phase 2 Trial buff.ly/3cHr5lk
1
2
Why aren't patients with MCI or dementia diagnosed early ? rdcu.be/b3DUZ #JPAD #Alzheimer #MCI
New Post: CHMP Favors Zeposia (Ozanimod) as Oral Treatment for Active RRMS in EU buff.ly/3bNcV1N
1
1
In-vivo staging of regional amyloid deposition predicts functional conversion in the preclinical... - goo.gl/scholar/yKawMn #ScholarAlerts
Please reTweet to help raise awareness that not all #dementia is Alzheimer's disease.There are 100+ different types of dementia, including #Alzheimers. Learn more: alz.co.uk/about-dementia
5
152
10
141
New Post: BTK Inhibitor SAR442168 Reduces New Lesions in MS Patients, Phase 2 Clinical Trial Results Show buff.ly/3biOf1n
White Matter Hyperintensities and #Alzheimers Pathology Associated with Cognitive Impairment Risk journals.lww.com/neurotodayo… via @NeurologyToday #dementia #neurology @JBarbosaPR @MarcMordey @jdjongumzidenga @guse_guse @emocionycambio @jvicenteprieto @niksnook57 @mokomokai @je_pala
16
18
Today is World #EpilepsyDay. #Epilepsy affects around 50 million people worldwide, making it one of the most common neurological diseases globally. https://nitter.cf/t.co/BAV5WFD3Hd
31
668
52
879